The authors have advised that there is an error in the article “Guidelines for the management of ulcerative colitis. Recommendations of the Polish Society of Gastroenterology and the Polish National Consultant in Gastroenterolog” paper.
Page 10. The sentences “Vedolizumab is administered first in induction therapy by intravenous infusion (300 mg in a 0–2–6 week regimen), and then in maintenance therapy by intravenous infusion (300 mg every 8 weeks). An additional dose of the drug is allowable at week 10 after treatment initiation if no discernible clinical benefit has been obtained after 3 induction doses. Also maintenance therapy dosing can be intensified, by administering 300 mg intravenously every 4 weeks, depending on the clinical presentation.” should read “Vedolizumab is administered first in induction therapy by intravenous infusion (300 mg in a 0–2–6 week regimen), and then in maintenance therapy by intravenous infusion (300 mg every 8 weeks). The maintenance therapy dosing can be intensified, by administering 300 mg intravenously every 4 weeks, depending on the clinical presentation.”
The article has since been corrected online.
